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a b s t r a c t
Thrombotic thrombocytopenic purpura (TTP, Moschcowitz disease) is characterized by
thrombotic microangiopathy leading to microvascular occlusion and ischemic dysfunction
of various organs including the brain. In the course of the rare disease most patients develop
neurological symptoms of varying severity and characteristics. The case presented is that of
a 34-year-old female patient with profound thrombocytopenia, anemia and rapidly pro-
gressive neurological deterioration into coma with normal result of brain imaging. TTP was
recognized on the basis of hematological analysis. The initiated steroid therapy and plasma
exchange failed to prevent the turbulent course of disease in the patient, who died exhibiting
symptoms of multiple organ failure caused by thrombotic microangiopathy. TTP remains to
be a diagnostic challenge, particularly in the case of atypical symptoms or when neuroim-
aging and laboratory results are inconclusive. Before using the corticosteroids and plasma
exchange, TTP had a case fatality rate of approx. 90% (Podolak-Dawidziak, 2013). Nowadays
recovery is possible when vigorous treatment is introduced early in the course of this
disease.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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A 34-year-old woman was admitted to the Department of
Internal Medicine due to general weakness and subfebrile
state, both of which appeared four days earlier. In the week
before admission, she had a mild infection of the upper
respiratory tract; otherwise her individual and family inter-
view did not reveal any burden. She did not use any chronic
treatment. The following results were found in the course of* Corresponding author at: Oddział Neurologii, Samodzielny Publiczny
Centrum Medyczne im. Prof. Leszka Gieca, ul. Ziołowa 45/47, postal code
E-mail address: alasek@gcm.pl (A. Lasek-Bal).
http://dx.doi.org/10.1016/j.pjnns.2014.07.002
0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Udiagnostic procedures: thrombocytes 8000/ml, red blood cell
(RBC) count 2.9  106/ml, low hemoglobin (Hb) 8.14 g/dl, white
blood cell (WBC) count 9400/ml; normal biochemical hepatic
and renal parameters and normal results of abdomen
ultrasound examination, gastroscopy and chest X-ray.
On the second day of hospitalization, a transient speech
disturbance in the form of motor aphasia and numbness of the
right cheek appeared twice within a few hours; these lasted
several minutes and resolved without residual symptoms. The
consulting neurologist found no signiﬁcant deviations in the Szpital Kliniczny Nr 7 Śląski Uniwersytet Medyczny, Górnośląskie
 40-735 Katowice, Poland. Tel.: +48 32 359 83 06; fax: +48 32 202 95 92.
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and red blood cells were supplemented; however, that failed
to cause any signiﬁcant improvement in the morphotic
parameters.
Again, on the third day of hospitalization, the patient
experienced speech disturbances. Neurological examination
revealed mixed aphasia with predominant motor aphasia,
without other clinical symptoms. Computed tomography of
the head did not reveal any lesions. Within several hours, the
following signs appeared: body temperature of 38.5 8C,
increasing quantitative disturbances of consciousness. On
the following day, the patient was transferred to the Depart-
ment of Neurology, where, at the admission, the following
were found: body temperature of 38.1 8C, stupor (8/15 points on
the Glasgow Coma Scale), normal pupils, slight right-sided
hemiparesis with the Babinski sign present, no meningeal
syndrome. Magnetic Resonance Imaging (MRI) of the head
(with contrast enhancement and including DWI) did not reveal
any pathology within the intracranial structures. The blood
test revealed the following results: thrombocytes 5000/ul, RBC
2.6  106/ul, present erythroblasts, Hb 8.12 g/dl, WBC 13,400/ul,
D-dimers 9000.5 ng/dl (N up to 550 ng/dl), normal ionogram,
bilirubin and creatinine.
Due to profound thrombocytopenia lumbar puncture was
abandoned. Antibiotic therapy, virusostatic treatment, steroid
therapy and freshly frozen plasma were included as treat-
ment. There was a further increase of disorders of conscious-
ness, high body temperature and absence of meningeal
symptoms. On the second day of hospitalization in the
Department of Neurology, there was an increase in creatinine
concentration 1.17 mg/dl (N 0.5–0.95) and bilirubin concentra-
tion 4.47 mg/dl (N up to 1.2); proteinuria of 100 mg/dl also
occurred. The results obtained showed high levels of L-lactate
dehydrogenase (LDH): 2137 U/l (N 135–214), normal haploglo-
bin levels and antiglobulin test results, normal result of
serological tests for HIV infection, connective tissue diseases,
anti-cardiolipin antibodies, plasmatic coagulation factors and
procalcitonin.
After the analysis of the course of disease, the nature of
neurological symptoms and the results of imaging tests, it
was hypothesized that the nervous system was secondarily
affected in the course of immune-mediated hematological
disease. Given the persistent thrombocytopenia, anemia and
increasing kidney disorders thrombotic thrombocytopenic
purpura (Moschcowitz disease), hemolytic uremic anemia,
disseminate intravascular coagulation (DIC) and Evans
syndrome were considered in the ﬁrst place. The consulting
hematologist found schistocytes in the peripheral blood
smear and ultimately conﬁrmed the diagnosis of Moschco-
witz disease. Steroid therapy, supply of freshly frozen plasma
and red blood cell concentrate were continued. One session of
plasma exchange (PE) was performed, after which the
patient's state improved in terms of the state of wakefulness,
mobility of the right limbs; fever subsided. On the second day
after admission to the Department of Neurology, the patient
was transferred to the Department of Hematology for further
treatment, including the continuation of PE. However, the
patient's condition has signiﬁcantly worsened and she
died showing the symptoms of acute respiratory failure.
Autopsy indicated multiple organ failure in the course ofthrombocytopenic purpura, with small hemorrhagic infarc-
tion in the pancreas and an area of myocardial necrosis.
Histological evaluation showed diffuse vascular lesions with
severe involvement of large artery branches, medium-sized
arteries and small vessels with arterial occlusion.
TTP was ﬁrst described in 1924 by Moschcowitz in relation
to a patient with the following triad of symptoms: thrombo-
cytopenia, hemolytic anemia and variable atypical neurologi-
cal symptoms [2]. The ﬁrst description of the disease presented
in the literature is an accurate characterization of the clinical
image of TTP in our patient.
Thrombotic thrombocytopenic purpura (TTP, Moschcowitz
disease) is a thrombotic microangiopathy with thrombocyto-
penia caused by intravascular platelet aggregation. Formation
of blood clots in the capillaries and small arterioles is caused
by endothelial damage and the presence of von Willebrand
factor multimers (unusually large multimers of von Will-
ebrand factor, UlvWF) binding to thrombocyte receptors. The
metalloproteinase binding antibody ADAMS13 (disintegrin
and metalloproteinase with thrombospondin-1-like domain)
that disintegrates the UlvWF molecules, which prevents their
proper degradation, is present in the acute phase of the
disease. Additionally, damage occurs to the erythrocytes,
which is associated with the presence of platelet aggregates in
the microcirculation and is conﬁrmed by the presence of
schistocytes in peripheral blood smear [3]. Ischemia of various
organs, including the nervous system, occurs as a result of
disturbances in the microcirculation. The disease, more often
affecting women aged 30–40, starts suddenly and is often
preceded by a mild upper respiratory infection. TTP may be
either drug-induced or it may accompany a neoplastic disease.
Its clinical course reveals the presence of fever, symptoms of
hemorrhagic diathesis and hemolysis (anemia, icterus),
petechiae on the skin of limbs and trunk and on the mucous
membrane of oral cavity, abdominal pain and neurological
symptoms with varying characteristics in the majority of
patients. The DIC syndrome develops in approximately 10% of
patients [1].
The laboratory results reveal normocytic anemia, erythro-
blasts and schistocytes, thrombocytopenia, reticulocytosis,
increased bilirubin, increased LDH activity, proteinuria and
negative Coombs reactions. The course of the disease is violent
at times, and if untreated, it leads to death in approximately
90% of patients [1,4].
Steroids (Methylprednisolone 0.75 mg/kg intravenously
every 12 h for 1–4 weeks) with transfusion of freshly frozen
plasma (40–60 ml/kg/d) and PE are applied in treatment. In
patients refractory to PE, Rituximab is recommended (intrave-
nously 375 mg/m2 within the ﬁrst 3 days or 375 mg/m2 weekly
for 4–8 weeks). In patients with exacerbation during steroid
therapy or treatment with Rituximab-vincristine is applied
(1.4 mg/kg intravenously for 3 days and from the 4th day)
follow up by cyclophosphamide or azathioprine. The role of
splenectomy in the current management of TTP is limited. It
causes improvement in some patients within the remission
period after the ﬁrst relapse. The supplementation of red blood
cells is also important. The application of platelet concentrate
increases thrombosis [1,5–7].
The case presented here relates to a female patient with
TTP whose neurological symptoms were dominant in the
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common symptoms of damage to the nervous system are
headaches, motor deﬁcits, seizures and coma [8,9]. In most
cases, coma is preceded by focal symptoms or seizures [10]. It
has less often been described in the absence of focal
neurological deﬁcits or seizures [11]. Kelly et al. presented
two cases with confusion and drowsiness developing into
coma who both fully recovered after plasma exchange [12].
The cause of neurologic symptoms in TTP is cerebral
angiopathy leading to cerebral hypoperfusion in relation to
endothelial dysfunction, impaired reactivity of the small
cerebral arteries, damage to the blood-brain barrier and
vasogenic edema. MRI reveals ischemic and/or hemorrhagic
foci; an image resembling reversible posterior encephalopathy
has been also described. Infarcts of the brain may be multifocal
cortical or lacunar; they may be located within periventricular
region and in the areas supplied by large cerebral arteries [13].
Thrombocytopenia and the increase in blood pressure in the
course of renal failure play an important role in the
hemorrhagic transformation of ischemic foci or spontaneous
brain hemorrhages. The lack of lesions in our patient's MRI of
the head, despite the neurological symptoms, may be
associated with the early period of examination when the
neurological symptoms were caused by microcirculation.
Conﬂict of interest
None declared.
Acknowledgement and ﬁnancial support
None declared.
Ethics
The work described in this article has been carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans; Uniform Requirements for manuscripts submit-
ted to Biomedical journals.r e f e r e n c e s
[1] Podolak-Dawidziak M. Niedokrwistości. Interna Szczeklika-
Podręcznik Chorób Wewnętrznych 2013. Kraków: Medycyna
Praktyczna; 2013 [chapter D 6].
[2] Moschcowitz E. An acute febrile pleiochromic anemia with
hyaline thrombosis of the terminal arterioles and
capillaries: a hitherto undescribed disease. Proc NY Pathol
Soc 1924;24:21–4.
[3] Blombery P, Scully M. Management of thrombotic
thrombocytopenic purpura: current perspectives. J Blood
Med 2014;5:15–23.
[4] Sundram F, Roberts P, Kennedy B, Pavord S. Thrombotic
thrombocytopenic purpura associated with statin
treatment. Postgrad Med J 2004;80(947):551–2.
[5] Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen
H, et al. A phase 2 study of the safety and efﬁcacy of
rituximab with plasma exchange in acute acquired
thrombotic thrombocytopenic purpura. Blood 2011;118
(August (7)):1746–53.
[6] Jiang H, An X, Li Y, Sun Y, Shen G, Tu Y, et al. Clinical
features and prognostic factors of thrombotic
thrombocytopenic purpura associated with systemic lupus
erythematosus: a literature review of 105 cases from 1999 to
2011. Clin Rheumatol 2014;33(3):419–27.
[7] Allford SL, Hunt B, Rose P, Machin S, Haemostasis and
Thrombosis Task Force, Brotish Committee for Standards in
Haemotology. Guidelines on the diagnosis and
management of the thrombotic minroangiopathic
haemolytic anaemias. Br J Haematol 2003;120:556–73.
[8] de Jong F, Te Boekhorst PA, Dippel DW, Jacobs BC. Coma in
thrombotic thrombocytopenic purpura. BMJ Case Rep
2010;23:2010.
[9] Godlewski A, Szczech J. A case of Moschkowitz syndrome
(thrombotic thrombocytopenic purpura). Neurol Neurochir
Pol 1987;21(November–December (6)):548–51.
[10] Pandey S. Seizure in patients with thrombotic
thrombocytopenic purpura. Arch Neurol 2010;67(12):1536.
[11] Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B,
Benjamin S, et al. Regional UK TTP registry: correlation with
laboratory ADAMTS 13 analysis and clinical features. Br J
Haematol 2008;142:819–26.
[12] Kelly FE, Treacher DF, Williams FM, Hunt BJ, Howard S.
Coma in thrombotic thrombocytopenic purpura. J Neurol
Neurosurg Psychiatry 1999;66:689–90.
[13] Bas D, Oguz KK, Topcuoglu MA. Atypical reversible
posterior leukoencephalopathy syndrome in thrombotic
thrombocytopenic purpura. Intern Med 2008;47(21):1931–4.
